Significant Increase in High-Density Lipoprotein Cholesterol with Fibrates Is Associated with Low Pretreatment High-Density Lipoprotein Cholesterol: Findings from an Outpatient Clinic Setting

Ramachandran, Selvakumar; Abbas, Ahmad; Saraf, Sanjay; Raju, Jessie; Jewkes, Christina; Jones, Alan

doi:10.1089/met.2011.0112

Cited by 8 publications

(4 citation statements)

References 31 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant changes were seen in TC, TG and HDL-C following fibrate treatment. These findings were anticipated as our patient group was a subset of the cohort previously reported regards the above analytes (Ramachandran et al, 2012; Abbas et al, 2012). All three LFT studied decreased (Table 1) with fibrate treatment with paired t -Test showing the changes to be significant; GGT (p < 0.0001), ALT (p = 0.0014) and ALP (p < 0.0001).…”

Section: Resultsmentioning

confidence: 63%

Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundFibrates are used especially in patients with hypertriglyceridaemia, a feature of the metabolic syndrome. Elevated LFTs are often observed in these patients perhaps related to fatty infiltration.AimWe wished to study changes seen in LFTs (GGT, ALT and ALP) following fibrate therapy and then determine associated factors.MethodsThis was a retrospective observational study in which data was collected from case notes of patients started on fibrates (n = 118, 2002–2008) in the lipid clinic at Good Hope Hospital and pre/post-fibrate lipid and LFT values were obtained. All biochemistry was performed on the Roche P-Unit using supplied reagents. Statistical analyses included t tests and regression analyses (factorised when quartiles were compared).ResultsOf the study population 106 patients were on fenofibrate; the remaining on bezafibrate. Significant lowering of GGT (p < 0.0001), ALT (p = 0.0014) and ALP (p < 0.0001) levels were observed following fibrate treatment. Baseline lipid (cholesterol, triglycerides and HDL) concentrations, alcohol intake, length of treatment, gender, concurrent statin treatment and diabetes did not correlate with these changes in LFT in a multiple regression analysis. Higher pre-fibrate GGT (p < 0.0001), ALT (p < 0.0001) and ALP (p < 0.0001) concentrations were associated with larger decreases in each of these tests respectively with the highest 2 quartiles (GGT > 57 IU/l, ALT > 34 IU/l and ALP > 94 IU/l) significantly different to the lowest quartile. The above associations remained significant even when the regression analyses were corrected for changes in lipid values (which did not show an association).ConclusionsFibrate treatment led to improvements in LFT, the greatest benefit seen in patients with higher baseline LFT values. It appears that baseline and changes in lipid values post fibrate treatment were not associated with change in LFT.

show abstract

Section: Resultsmentioning

confidence: 63%

Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our opinion, many chronic pathologies are heterogeneous, with common phenotypes leading them to be grouped as single diseases . We have previously shown that statins and fibrates exert greater effects in certain dyslipidaemic subgroups . With HG heterogeneity in mind, we wished to identify subgroups where the previously observed associations were more marked.…”

Section: Discussionmentioning

confidence: 99%

Long‐term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors

et al. 2018

View full text Add to dashboard Cite

show abstract

“…1a), is used for hypercholesterolemia and hypertriglyceridemia to reduce morbidity and mortality associated with cardiovascular disease as a lipid regulating agent [1][2][3][4]. FF is absorbed from the gastrointestinal tract, and is principally hydrolysed by the CYP3A4 isozyme to its active and major metabolite fenofibric acid (FFA, Fig.…”

Section: Introductionmentioning

confidence: 99%

Determination of Fenofibric Acid in Human Plasma by LC–MS/MS and LC–UV

Arafat

Awwad

et al. 2016

Chromatographia

View full text Add to dashboard Cite

systems during validation, and accuracies ranged between 91 and 112 %. Twenty-eight healthy adult subjects participated in this clinical study, and the pharmacokinetic parameters including coefficient of variation were calculated and discussed. A dramatic decrease in C max and AUC0-72 (3.63-and 1.85-fold, respectively) were observed for Lipanthyl™ MC under fasting conditions with more variable inter subject measurements comparing to the fed state.

show abstract

Significant Increase in High-Density Lipoprotein Cholesterol with Fibrates Is Associated with Low Pretreatment High-Density Lipoprotein Cholesterol: Findings from an Outpatient Clinic Setting

Cited by 8 publications

References 31 publications

Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome

Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome

Long‐term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors

Determination of Fenofibric Acid in Human Plasma by LC–MS/MS and LC–UV

Contact Info

Product

Resources

About